A5079748913- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Autoimmune and Inflammatory Disorders Research
- Spondyloarthritis Studies and Treatments
- Musculoskeletal pain and rehabilitation
- Monoclonal and Polyclonal Antibodies Research
- Psoriasis: Treatment and Pathogenesis
- Peripheral Neuropathies and Disorders
- Cytokine Signaling Pathways and Interactions
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Health Systems, Economic Evaluations, Quality of Life
- Pain Management and Placebo Effect
- Toxin Mechanisms and Immunotoxins
- Inflammatory Myopathies and Dermatomyositis
- Cancer Immunotherapy and Biomarkers
- Inflammasome and immune disorders
- Bladder and Urothelial Cancer Treatments
- Musculoskeletal synovial abnormalities and treatments
- T-cell and B-cell Immunology
- HER2/EGFR in Cancer Research
- Eosinophilic Disorders and Syndromes
- Musculoskeletal Disorders and Rehabilitation
Cardiff University
2016-2025
Tenovus Cancer Care
2012-2025
Institute of Infection and Immunity
2013-2025
Cedars-Sinai Medical Center
2025
University Hospital of Wales
2014-2023
Centre de recherche en Epidémiologie et Santé des Populations
2022
Cardiff and Vale University Health Board
2018-2021
ASST Fatebenefratelli Sacco
2021
Luigi Sacco Hospital
2021
Columbus Oncology and Hematology Associates
2021
Abstract Objective Adalimumab, a fully human, anti–tumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA). Methods Patients moderately to severely PsA history inadequate response nonsteroidal antiinflammatory drugs were randomized receive 40 mg adalimumab or subcutaneously every other week 24 weeks. Study visits at baseline, weeks 2 4, 4 thereafter. The primary end points American College...
Abstract Objective To investigate the safety and efficacy of MRA, a recombinant human anti–interleukin‐6 (anti–IL‐6) receptor monoclonal antibody IgG1 subclass that inhibits function IL‐6, in patients with established rheumatoid arthritis (RA). Methods A randomized, double‐blind, placebo‐controlled, dose‐escalation trial was conducted 45 active RA, as defined by American College Rheumatology (ACR) revised criteria. Patients were sequentially allocated to receive single intravenous dose...
Abstract Introduction We analyzed the prevalence of cardiovascular (CV) disease in patients with rheumatoid arthritis (RA) and its association traditional CV risk factors, clinical features RA, use disease-modifying antirheumatic drugs (DMARDs) a multinational cross-sectional cohort nonselected consecutive outpatients RA (The Questionnaires Standard Monitoring Patients Rheumatoid Arthritis Program, or QUEST-RA) who were receiving regular care. Methods The study involved assessment by...
Objective. We determined the amount of fatigue experienced by patients with RA, and its relationship to synovitis, pain other common clinical features. also examined what extent RA is improved disease-modifying antirheumatic drugs (DMARDs) anti-tumour necrosis factor (TNF) therapy. Methods. studied two cohorts 238 274 cross-sectionally treatment responses in 30 starting anti-TNF 54 DMARDs followed for 3 6 months. measured using visual analogue scores (VAS) Medical Outcomes Study Short Form...
<h3>Objective:</h3> To develop evidence-based recommendations for the management of systemic glucocorticoid (GC) therapy in rheumatic diseases. <h3>Methods:</h3> The multidisciplinary guideline development group from 11 European countries, Canada and USA consisted 15 rheumatologists, 1 internist, rheumatologist–epidemiologist, health professional, patient research fellow. Delphi method was used to agree on 10 key propositions related safe use GCs. A systematic literature search PUBMED,...
Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These can be considered have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking.The Task Force in charge "Development EULAR recommendations for comprehensive difficult-to-treat arthritis" aims create this underserved patient group. Herein, we present RA, as first step.The Steering Committee...
Over the years, many have viewed Fibromyalgia syndrome (FMS) as a so-called "functional disorder" and patients experienced concomitant lack of interest legitimacy from medical profession. The symptoms not been explained by peripheral mechanisms alone nor specific central nervous system mechanisms. In this study, we objectively evaluated cerebral response to individually calibrated pain provocations pain-free body region (thumbnail). study comprised 16 female FMS age-matched controls. Brain...
Interleukin 6 (IL-6) is a pleiotropic cytokine with pivotal role in the pathophysiology of rheumatoid arthritis (RA). It found abundance synovial fluid and serum patients RA level correlates disease activity joint destruction. IL-6 can promote synovitis destruction by stimulating neutrophil migration, osteoclast maturation vascular endothelial growth factor (VEGF)-stimulated pannus proliferation. may also be mediating many systematic manifestations including inducing acute-phase reaction...
Highlights•Deep phenotyping and RNA-seq of early rheumatoid arthritis individuals pre-treatment•Synovial plasma cell gene expression predicts future progressive joint damage on X-ray•Blood interferon signature associates with synovial B infiltration•Interactive website enables clinical data to be fully exploredSummaryThere is a current imperative unravel the hierarchy molecular pathways that drive transition established disease in (RA). Herein, we report comprehensive RNA sequencing analysis...
Abstract Objective To evaluate the efficacy and safety of treatment with adalimumab, a fully human anti–tumor necrosis factor (anti‐TNF) monoclonal antibody, over 48 weeks in patients moderate to severe psoriatic arthritis (PsA). Methods Patients who completed Adalimumab Effectiveness Psoriatic Arthritis Trial (ADEPT), 24‐week, double‐blind study adalimumab versus placebo PsA, could elect receive open‐label 40 mg subcutaneously every other week after 24. Radiographs were obtained at read...
Abstract Background Fibromyalgia is a painful, debilitating illness with prevalence of 0.5-5.0% that affects women more than men. It has been shown the diagnosis fibromyalgia associated improved patient satisfaction and reduced healthcare utilization. This survey examined journey to having their condition diagnosed studied impact on life. Methods A questionnaire 800 patients 1622 physicians in 6 European countries, Mexico South Korea. Patients were recruited via physician. Results Over half...
Objectives To unravel the hierarchy of cellular/molecular pathways in disease tissue early, treatment-naïve rheumatoid arthritis (RA) patients and determine their relationship with clinical phenotypes treatment response/outcomes longitudinally. Methods 144 consecutive early RA (<12 months symptoms duration) underwent ultrasound-guided synovial biopsy before 6 after disease-modifying antirheumatic drug (DMARD) initiation. Synovial biopsies were analysed for cellular (immunohistology)...